SavedAdd your journal

Journals / Anadolu Psikiyatri Dergisi / 2010 / Cilt: 11 - Sayı: 1

Efficiency and tolerability of OROS-methylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder

Dikkat eksikliği hiperaktivite bozukluğu tanılı Türk çocuklarında OROS-metilfenidatın etkinlik ve güvenilirliğinin değerlendirilmesi

Yıldız Özlem ÖÇ
Belma AĞAOĞLU
Işık KARAKAYA
Şahika G. ŞİŞMANLAR
NURSU ÇAKIN MEMİK
Pages
44–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results demonstrated that both drugs were effective and well tolerated in the treatment of Turkish children with ADHD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the study was to compare efficacy and tolerability of OROS-methylphenidate HCL (OROS-MPH) with immediate-release methylphenidate (IR-MPH) in Turkish children with attention-deficit/hyperactivity disorder (ADHD).
📊
Key Findings & Data:Methods: This study was designed as an open label, prospective, for an 8-week period.
💡
Conclusion & Impact:These results demonstrated that both drugs were effective and well tolerated in the treatment of Turkish children with ADHD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the study was to compare efficacy and tolerability of OROS-methylphenidate HCL (OROS-MPH) with immediate-release methylphenidate (IR-MPH) in Turkish children with attention-deficit/hyperactivity disorder (ADHD). Methods: This study was designed as an open label, prospective, for an 8-week period. A total of 83 subjects, between the ages of 7 and 14 with ADHD, were included in this study. The dosages of OROS-MPH and IR-MPH were adjusted by the investigators based on symptoms and adverse events assessments performed (OROS-MPH doses: 18-36 mg/day-once daily, IR-MPH doses:10-20 mg/day-divided dose). The efficacy and adverse effects of the drugs were assessed due to Turgay DSM-IV-Based Child and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S), Clinical Global Impression-Global improvement Scale (CGI-GI), and Methylphenidate Side Effects Rating Form (MSERF). Results: Both OROS-MPH and IR-MPH showed definitive improvement of severity symptoms of ADHD (p<0.05). No significant differences were found between two groups at 8th week in mean scores of T-DSM-IV and CGI-GI. Weight loss was found to be related with the dose increase according to parents&#8217; reports on adverse effects of OROS-MPH. Conclusion: OROS-MPH was found to be as effective as IR-MPH in the treatment of behavioral symptoms in Turkish children with ADHD. These results demonstrated that both drugs were effective and well tolerated in the treatment of Turkish children with ADHD.

Özet

Amaç: Bu çalışmada dikkat eksikliği hiperaktivite bozukluğu (DEHB) tanılı Türk çocuklarında OROS-metilfeni-datın (OROS-MPH) etkinlik ve güvenilirliğinin kısa etkili metilfenidat (IR-MPH) ile karşılaştırılması amaçlanmıştır. Yöntem: Bu çalışma açık uçlu, ileriye dönük, 8 haftalık bir çalışma olarak planlandı. DEHB tanılı, 7-14 yaşları arasında toplam 83 çocuk çalışmaya alındı. OROS-MPH ve IR-MPH dozları çalışmacılar tarafından belirti ve yan etkiler değerlendirilerek düzenlendi (OROS-MPH dozu: 18-36 mg/gün tek doz, IR-MPH dozu: 10-20 mg/gün bölünmüş doz). Etkinlik ve yan etki değerlendirmelerinde Çocuk ve Ergen Davranış Bozuklukları için DSM-IV’e dayalı Tarama ve Değerlendirme Ölçeği (T-DSM-IV-S), Klinik Global İzlem-Global İyileşme Ölçeği (KGİ-Gİ) ve Uyarıcı İlaçlar İçin Yan Etkileri Tarama Ölçeği (MSERF) kullanıldı. Bulgular: İki ilaç grubunda da DEHB belirti şiddetinde anlamlı düzeyde azalma olduğu gözlendi (p<0.05). Sekizinci haftada yapılan son değerlendirmede T-DSM-IV ve KGİ-Gİ puanlarında gruplar arasında anlamlı farklılık saptanmadı. Anne-babaların bildirimlerine göre kilo kaybı yan etkisi OROS-MPH grubunda dozla ilişkili bulundu. Sonuç: DEHB’li Türk çocuklarında davranışsal belirtilerin tedavisinde OROS-MPH, IR-MPH kadar etkili bulunmuştur. Bu sonuçlar DEHB’li Türk çocuklarının tedavisinde etkili ve güvenilir olduğunu göstermiştir.

🔖

Cite This Article

ÖÇ, Y. Ö., AĞAOĞLU, B., KARAKAYA, I., ŞİŞMANLAR, Ş. G., MEMİK, N. Ç. (2010). Efficiency and tolerability of OROS-methylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Anadolu Psikiyatri Dergisi, Cilt: 11 - Sayı: 1, 44–50. https://ajindex.com/articles/356189

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Farone SV, Sergeant J, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2:104-113
  2. AAP. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000; 105:1158-1170
  3. AACAP. Practice parameter fort he use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(Supl.2):26-48
  4. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphendate. Clin Pharmacokinet 1999; 37:457-470
  5. Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, et al. A comparison of morning only and morning/late afternoon Adderall to morning only, twice daily, and three times daily methylphenidate in children with attention deficit hyperactivity disorder. Pediatrics 1999; 104:1300-1311
  6. Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate fort he treatment of ADHD: Effects on activity level in classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002; 41:1306-1314
  7. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-aday formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder. Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003; 60:204-211
  8. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROS-Methylphenidate compared to usual care with immediate-release methylphenidate in attention-deficit/hyperactivity disorder. Can J Clin Pharmacol 2006; 13:50-62
  9. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS- Methylphenidate is safe and tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006; 16:351-356
  10. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural setting. Pediatrics 2001; 107:105-120
  11. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Mental Bozuklukların Tanısal ve Sayımsal Elkitabı, dördüncü basım (DSM-IV), E Köroğlu (Çev. Ed.), Ankara, Hekimler Yayın Birliği, 1995
  12. Turgay A. Çocuk ve Ergenlerde Davranım Bozukluk